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it as the determining causal agent and therefore promote vaccination as an effective prevention strategy.
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The pathogenesis of Human Papillomavirus (HPV) in the development of cervical
cancer: are HPV vaccines a safe and effective management strategy?
Judy Wilyman MSc

Abstract
Human Papillomavirus (HPV) infection has been linked with cervical cancer. Some medical professionals
see it as the determining causal agent and therefore promote vaccination as an effective prevention
strategy. However, the biological plausibility of a causal theory requires that the incidence of the
causal agent varies with the incidence and mortality of the disease. Yet the incidence and mortality of
cervical cancer do not vary with the incidence of infection with HPV strains 16 and 18; the strains
covered by the HPV vaccine. Though HPV infection is a necessary precursor to most cervical cancer,
most high-risk HPV infections (with one of 15 or more high–risk strains) do not progress to cervical
cancer and HPV infection with any strain is not sufficient on its own to induce cervical cancer. This
evidence supports the conclusion that environmental and lifestyle factors are a determining cause in
conjunction with HPV in the progression to cervical cancer.
Clinical trials for the HPV vaccine did not attempt to observe the vaccine preventing any cervical
cancer. Instead the trials looked for pre-cancerous lesions in women 16 – 26 years of age. This was an
inadequate surrogate for cervical cancer because studies show that most lesions in this demographic
clear quickly without requiring treatment. Preventing infection from HPV strains 16 and 18 also
assumes these women will not get cervical cancer from infection with one of the many other high risk
strains that are prevalent. Therefore the decision to use an HPV vaccine to prevent cervical cancer was
based upon circumstantial evidence: assumptions. HPV vaccines have been promoted to women on
selective information. This vaccine is an HPV vaccine not a cervical cancer vaccine. There is
inconclusive evidence it will reduce any cervical cancer and the long –term risks of using this vaccine
have not been determined.

Background
Cervical cancer has been studied worldwide for a century and a half and during this time many lifestyle
and environmental factors have been implicated in its etiology 1. However, by 1995 the discovery of
new hybridization technology led Bosch et al to claim “infection with HPV 16 and 18 is predictive of
carcinoma and independent of other factors” 2. In 2006, Munoz et al declared human papillomavirus
(HPV) Type 16 and 18 to be the determining cause of cervical cancer 3. These researchers stated “the
causal role of human papillomavirus in all cancers of the uterine cervix has been firmly established
biologically and epidemiologically” 3. This led to the release of a new vaccine to prevent HPV infection
in the same year. It was promoted to the public as a vaccine that prevents cervical cancer 4, 5.
At this time it was known that HPV infection on its own was not sufficient to cause cervical cancer 1, 6,
7. Several co-factors had been identified as necessary for the progression of normal epithelial cells to
carcinoma. Whilst there is still doubt about the identity of some co-factors, those that are confirmed
are: multiple partners for the male and female, presence of HPV plus other viruses (for example HPV +
Herpes Simplex Virus Type 2), prostitution, sex without a condom/microbicides, low socioeconomic
status (poor hygiene/sanitation/nutrition conducive to sexually transmitted diseases),
immunosuppression, smoking, oral contraceptives 1, 6, 7.
In addition, the plausibility of a causal theory, such as that put forward by Bosch et al, requires that
the incidence and mortality of a disease varies with the factors implicated in the cause of the disease
8. It also requires evidence that the disease develops only in cases where the virus is present 8. The
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strongest evidence for proving that HPV 16 and 18 are the central etiological factors in cervical cancer
worldwide would be a correlation between the incidence of HPV 16/18 worldwide and the incidence
and mortality of cervical cancer worldwide 8. This evidence would be strengthened by performing longterm prospective studies investigating biological and environmental factors that might operate in
conjunction with HPV infection and would provide empirical evidence of the cause of cervical cancer 8.
This is because these studies would include the correct follow up period or latent period between the
initiation of the cancer and its development many years later 8, 9. In the case of cervical cancer this
period has been estimated at about ten to twenty-five years 4, 9, 10.
However, long-term prospective studies to determine the causality of cervical cancer have not been
done 11. The pharmaceutical companies (manufacturers of the vaccine) that sponsored the trials for
HPV vaccines decided long-term studies would be too costly due to the latent nature of the disease 11.
In 1995 it was claimed that HPV DNA could be found in the majority of carcinomas 2. Prior to 1995 the
detection of HPV DNA in different tissues had been unreliable and the sensitivity of the results varied
with different technology 12. However, in 1995, it was being claimed that ‘new molecular biology
techniques were truly sensitive and specific’ 13.
These new techniques were used to re-analyse the Bosch et al, study that claimed 93% of tumors
contained HPV DNA 14. As a result it was concluded that 99.7% of tumors contained HPV DNA 14. In
other words, the basis for the claim that HPV is found in the majority of carcinomas was founded on a
new technique for detecting HPV DNA that was promoted as being ‘truly sensitive and specific’.
In 2003, it was stated that the role of HPV infection in the cause of cervical cancer was established and
the World Health Organisation (WHO) was encouraged to test HPV vaccines as a preventative for
cervical cancer; but not by observing actual cases of the disease 11. It was decided that a surrogate for
cervical cancer would be appropriate 11. The clinical trials for the vaccine used the occurrence of precancerous lesions in women 16 -26 years of age as the end-point for cervical cancer. This end-point was
used as a surrogate for proving the efficacy of the vaccine against cervical cancer in an age-group that
rarely gets cervical cancer 4, 11.
So despite evidence that co-factors are required for the progression of normal cells to cancer and
despite a lack of definitive evidence supporting the claim that HPV 16/18 are necessary and sufficient
to cause cancer, the HPV vaccine was promoted to all women as an effective preventative method. In
the following sections the validity of the claims that have been made about HPV vaccines are examined
from an historical perspective of etiology.

The Incidence of HPV Worldwide
There are over 100 HPV sub-types that have been identified and 40 of these are known to infect the
genital tract 3. Most strains of HPV are common and harmless, however there are at least 20 types
associated with cervical cancer: 14 of these are considered carcinogenic and these include HPV -16,
-18, -31, -33, -35, -39, -45, -51, -56, -58, -52, -26, -53, -66 2. These types are frequently found in
cervical cancer and are classified as ‘high-risk’ HPV’s 2. Other types such as HPV -6, -11, -42, -43 and
-44 are rarely associated with cervical tumors and they are classified as low risk HPV types 2 .
High rates of genital HPV infection are sustained in all communities throughout the world even in
groups that do not have a high partner exchange 6. As there are striking differences in the rate of
cervical cancer globally, it has been postulated that the more ‘high-risk’ HPV types may be associated
with higher rates of cervical cancer 6. The prevalence of HPV sub-types varies between communities
but the prevalence of HPV 16 and 18 does not correlate to regions with a high risk for cervical cancer
15. High-risk sub-types are found in both developed and developing countries yet women in developing
countries have a much greater risk of cervical cancer than woman in developed countries 16.
Some similarities in the distribution of HPV sub-types have been found in invasive cervical carcinomas
across regions 17. HPV 16 was found to be the dominant strain in all countries (51% of cases) and HPV
18 found consistently in 10-14% of cases 17. This led Clifford et al to claim that HPV 16 and 18 are
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found in approximately 70% of all ICC cases 17. Trends were also noticed in the prevalence of other
strains 2, 17.
Figure 1 illustrates a summary of the trends observed in the distribution of HPV sub-types in carcinomas
globally:

Figure 1: HPV type-specific prevalence by Geographic Region. Bosch FX, Manos M, Munoz N, Sherman M,
Jansen A, Peto J, Schiffman M, Moreno V, Kurman R, Shah K, International Biological Study on Cervical
Cancer (IBSCC), 1995, Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective,
Journal of the National Cancer Institute, Vol.87, No.11

The study by Clifford et al claimed two thirds of ICC was associated with HPV 16 and 18, yet these two
strains are not more prevalent in developing countries where the incidence of cervical cancer is highest
17. The prevalence of HPV 16 was higher in America, Australia and Europe: the developed countries
where the risk of cervical cancer is considered to be low 16. More than 16 high-risk HPV sub-types are
prevalent in all countries both in regions where the rates of cervical cancer are considered high and
where they are considered low 17. These sub-types include 45, 31, 33, 58, 39, 59 and 52 2, 17. This
trend can be observed in Figure 1.
Clifford et al state that heterogeneity in the distribution of high-risk HPV subtypes in different
populations should be taken into account when developing screening tests and predicting the effect of
vaccines on the incidence of HPV infection 15. The observed distribution of high-risk HPV sub-types led
Clifford et al to conclude a vaccine against HPV 16 and 18 may prevent a larger proportion of ICC in the
developed countries than in the developing countries 17. If this vaccine does not target the burden of
cervical cancer in the developing countries then it cannot claim to protect the population against 70%
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of cervical cancer. This statement was made the year before the vaccine was introduced into
developed nations and indicates there was no certainty of the effectiveness of this vaccine against
cervical cancer.
In addition, the claim by Clifford et al that HPV 16 and 18 are present in approximately 70% of ICC
cases needs to be examined with respect to the limitations of the study. The cases included in this
analysis were not representative of the burden of ICC worldwide 17. The study was under-represented
by cases from Africa and Asia which together represent 64% of cervical cancer cases and overrepresented by cases from Europe and North Africa that represent 20% of cervical cancer 17.
Another factor which puts doubt on this claim is the variation in the methods used to detect HPV in the
different studies that were included in the meta-analysis. The Clifford et al study combined the results
of 85 studies that used only Polymerase Chain Reaction (PCR) -based assays to identify HPV DNA 17.
However, not all PCR primer sets enhance HPV sub-types with the same sensitivity and this puts
uncertainty on the validity of the results of the meta-analysis 17.
An example of the variation in results obtained by using different PCR assays was the Bosch et al 1995
study. This study used MY09/11 polymerase chain reaction assay to detect HPV in 1000 tumors 2. HPV
was found to be prevalent in 93% of the tumors using this technique 2. However, when a different
detection method was applied it was found that HPV was prevalent in 99.7% of cervical carcinomas 14.
This allowed the researchers to conclude ‘a virtual absence of HPV-negative cancers (in 1000 tumors)
implies that effective prophylactic vaccination might eliminate cervical cancer worldwide’: even
though the 1000 cases were not representative of the global risk of cervical cancer 14. Appendix 1.
This claim led to the trial of an HPV vaccine to prevent cervical cancer even though the International
Agency for Research on Cancer (IARC) states case series can only provide suggestive results and can
never serve as a basis for causal inferences 6.

The Correlation between the Risk of HPV Infection and the Risk of Cervical Cancer Worldwide
The incidence of HPV infection in women worldwide is approximately 80 %, vastly greater than the
incidence of cervical cancer 16. The lifetime risk of cervical cancer before the age of 64 is 0.8 % in a
developed country and 1.5% in a developing country 16.
Figure 2 illustrates the variation of risk between developed and developing nations.

Developed Countries
per 100,000 women
0 – 14.5

Developing Countries
per 100,000 women
0.5 - 44

Figure 2: Incidence of Cervical Cancer Worldwide. Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global
Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108

In developed countries the risk of cervical cancer is considered very low 16. For example, in Australia
the incidence of cervical cancer is 6.9 /100,000 women and the death rate is 1.9/100,000 women 11.
Australia has one of the lowest rates of incidence and mortality from cervical cancer in the world: 99%
of Australian women will not be affected by cervical cancer in their lifetime 11. In Australia, indigenous
women have twice the risk of developing cervical cancer and the mortality rate is four times that of
non-indigenous women 11. In general Aboriginal communities in Australia are poorer communities and a
high incidence of cervical cancer is associated with these conditions 18. This variation of risk between
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indigenous and non-indigenous women indicates the significance of environmental and lifestyle factors
in the etiology of this disease.
In contrast, the risk of cervical cancer in developing countries is considered to be high 16. In the 60’s
and 70’s, developed countries had similar rates of cervical cancer to developing countries today 16.
China has also seen a dramatic decline in the incidence of cervical cancer from 17.8 per 100,000
women in 1985 to 6.8 in 2002 16. Developed countries have had improved living standards and greater
access to screening programs and condoms since the 1960’s. In addition, the incidence of HPV infection
is similar between all countries but the incidence of cervical cancer is not 6. This also supports the
theory that lifestyle and environmental risk factors act in conjunction with HPV infection to cause
cervical cancer.
It should be noted that the mortality rates for cervical cancer are lower than incidence rates 16.
Figure 3 illustrates this difference.

Developed Countries
per 100,000 women
0 - 10

Developing Countries
per 100,000 women

10 - 34

Figure 3: Mortality Rates for Cervical Cancer Worldwide. Parkin DM, Bray F, Ferlay J, Pisani P, 2005, Global
Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108

A comparison of the incidence and mortality rates for cervical cancer between countries is illustrated
in Figure 4 (below). This graph shows that mortality rates are lower than incidence rates for cervical
cancer and this disease is a much higher risk in developing countries than developed countries. The
difference in the risk of cervical cancer between countries has not been emphasised to women in the
education campaigns for this disease.
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Figure 4: Age-standardized Incidence and Mortality Rates for Cervix Uteri Cancer. Parkin DM, Bray F, Ferlay J,
Pisani P, 2005, Global Cancer Statistics 2002, CA: A Cancer Journal for Clinicians, 2005; 55; 74-108

Analysis of the evidence for HPV as the determining cause of cervical cancer
HPV are a group of viruses with strong epitheliotrophic properties; that is, they have a strong affinity
for epithelial cells 19. Epithelial cells normally harbor the virus and 80% of women are infected with
HPV during their lifetime 19. Therefore a significant association between HPV and invasive cervical
cancer (ICC) is expected 19. In 1989 it was unclear whether HPV was a passenger virus in carcinoma
development or whether it played a causal role in the progression to ICC 19. The overall evidence in
1989 pointed to a multi-factorial cause of cervical cancer as other determinants consistently emerged
as independent risk factors in epidemiological investigations 20.
The conclusion that HPV is the determining causal factor in cervical cancer development has been
based upon the research by Bosch et al investigating the worldwide prevalence of HPV in 1000 cervical
cancer tumors 2.
Epidemiologists claim there is a “highly statistically significant association between HPV and the
development of cervical intraepithelial neoplasia (CIN) grade 2 or 3 with persistent CIN 2/3 and with
development of cervical cancer” 1. Carcinogenicity of HPV 16 and 18 is supported by experimental
evidence that proteins of these viruses interfere with the functions of cellular regulatory pathways 6.
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However, Walboomers et al state “whilst persisting infection of the cervix with high-risk HPV is
necessary for the development of cervical cancer, it is certainly not sufficient” 14.
There would be strong evidence for HPV as the main independent cause of cervical cancer if the
majority of cases of infection with HPV 16 and 18 progressed to cervical cancer. But they do not. The
Australian Government states cervical cancer is a rare outcome of high-risk HPV infection and this is
supported by the International Agency for Research on Cancer (IARC) 6, 7. In addition, it would be
expected that the incidence and mortality of cervical cancer would vary with the incidence of HPV 16
and 18 across the globe if these strains are the determining cause of most cervical cancer. We have
already observed that there is no correlation between the incidence of cervical cancer and incidence
of high-risk HPV sub-types, including HPV 16/18, so it is necessary to examine the influence of lifestyle
and environmental factors as co-factors in cancer development.

The Evidence for an Etiological Association with Environmental and Lifestyle factors
For many decades public health scientists have used the epidemiological triangle, consisting of host,
agent and environment, to assist in determining the etiology of infectious disease 8. This model of
causality has been revered as “one of the fundamental public health concepts of disease causality and
well suited to determining the cause of infectious diseases” 8.
Whilst an agent must be present for an infection to occur, other factors, such as the characteristics of
the environment and the host, also play a role in determining whether events progress to an active
case of the disease 8. This public health fact and the evidence cited here show that the claim by Bosh
et al (1995) that “infection with HPV 16 and 18 is predictive of carcinoma and independent of other
factors” is false 2. Evidence for this conclusion is summarised below:

1. HPV infection with any strain is not sufficient to cause cervical cancer 7.
2. Approximately eighty percent of women are infected with HPV yet ninety percent of these HPV
infections do not lead to cancer or warts 6, 7.

3. HPV 16 is identified as the pre-dominant sub-type in all countries yet cervical cancer rates vary
significantly between countries 16.

4. Developed countries had the same high rates of cervical cancer in the sixties and seventies as the

developing countries today but this was reduced by changes in environmental and lifestyle factors
and the introduction of screening 16.

5. There is an increased risk of cervical cancer with an increased number of sexual partners 6.
6. Prostitutes have a four times greater chance of getting cervical cancer even though the detection
of HPV sub-types is similar to controls 21.

7. Condoms can reduce the risk of cervical cancer four-fold 9.
8. China had a high rate of cervical cancer in 1985 but this was reduced to a low rate by 2002
without the use of a vaccine 16.

9. Bosch et al highlight that the sensitivity of new molecular biology techniques confirm the
plausibility of HPV infection as the pre-cursor event leading to cervical cancer 2. However, a precursor event is not predictive of cancer if the majority of cases do not progress to cancer.

10. Some scientists still claim 5-10% of tumors are not associated with any HPV DNA 1, 22.
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11. It is postulated that HPV 16 and 18 are present in possibly 70% of tumors but it has not been
proven 15. This statistic is dependent upon the detection methods used and still leaves 30% of
cervical cancer unprotected by the vaccine.

The use of Pre-cancerous Lesions in the Determination of Efficacy for the Vaccine
The WHO consultation group used four key features to suggest that observing the frequency of precancerous lesions (the virological endpoint of persistent HPV infection) in young women was a useful
endpoint for testing a vaccine against cervical cancer 11. These features were:

1. They are obligate precursors of cervical cancer
2. They are closely associated in temporal sequence to the development of invasive cervical
cancer

3. They are associated with a high risk of development of invasive cervical cancer (ICC)
4. Reductions in incidence or treatment are shown to result in a reduction in risk of invasive
cervical cancer.

The first three statements above are only true when the environmental and lifestyle risk factors (listed
above) are also present 1, 6, 7. Yet the clinical trials for this vaccine did not select participants for
these risk factors 23. The fourth statement needs to be qualified because cervical cancer is a rare
outcome of high-risk HPV infection and there are many high-risk subtypes 6, 7. There is no evidence
that just targeting HPV 16/18 will result in a significant reduction in the risk of cervical cancer. In
order to suggest that this vaccine will be effective in reducing the burden of cervical cancer, it must be
demonstrated that there is a correlation between the worldwide incidence of HPV 16 and 18 and
mortality from cervical cancer. This has not been demonstrated.
Pre-cancerous lesions were chosen as the end-point for cervical cancer based upon two assumptions 11:

1. The first assumption is that pre-cancerous lesions in this age group most often lead to cancer
23. This assumption is incorrect. Pre-cancerous lesions in this age group are most often cleared
quickly by the immune system 7, 10. It is also known that pre-cancerous lesions can persist for
a lifetime without giving rise to cervical cancer 7.

2. The second assumption underpinning these clinical trials is that preventing strains 16 and 18
from infecting women will prevent some cervical cancer. However, the prevention of strains 16
and 18 from infecting provides an opportunity for one of the many other high-risk HPV types to
infect; there are about 20 of these 6. The Australian health department confirms that resolved
infection with a high-risk HPV does not protect against other high-risk types 7.

The two assumptions described above confirm that using the occurrence of pre-cancerous lesions, in 16
-26 year olds, was an inappropriate end-point for cervical cancer development. This is because the
relationship between HPV infection at a young age and development of cervical cancer 20 to 40 years
later is unknown 24. In addition, the fact that HPV of all sub-types is found in high frequency among
women with normal cervices indicates that on its own HPV is not predictive of cancer 15.
Ninety percent of HPV infections have no clinical consequences at all: there is no development of
genital warts or progression to cervical cancer 6, 7. In 1990, Pfister noted ‘no papillomavirus is able to
induce cancer right away and fully on its own’ (p.6, 12). Carcinomas usually develop only after primary
lesions persist for several months/years, which indicates that additional events are needed to trigger
malignant growth 12.
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Efficacy of the HPV Vaccine
The trials investigating the efficacy of HPV 16/18 vaccine in preventing cervical cancer observed that
women, 16-26 years old, who were given the vaccine, had fewer pre-cancerous lesions than women
who were not given the vaccine 23. However, this result was dependent upon the protocol of the study
group 23. A significant reduction in pre-cancerous lesions was only observed in the study group that had
not been infected with HPV 16/18 at baseline 23.
The health department states that the HPV vaccine does not prevent HPV infection (16 and 18) which
was already present at the time of vaccination 7. The trials demonstrated only 44% efficacy in the
study group that was infected with HPV 16/18 at baseline 25. Previous sexual activity is the main
reason for infection with HPV 7. In other words, you are still susceptible to cervical cancer if you were
infected with HPV 16/18 prior to vaccination. This would be a large percentage of the population if
HPV 16/18 are the dominant sub-types, as scientists are claiming.
Since the vaccine was marketed in 2006 there has been no screening for HPV sub-types prior to
vaccination so there is no conclusive data on the effectiveness of this HPV vaccine in preventing precancerous lesions in a demographic that rarely gets cervical cancer. Currently the only clinical trials
that have been performed for this vaccine were funded by the manufacturers of the vaccine 23.
The manufacturer of HPV vaccines claims the drug prevents “high-grade disease” based on its ability to
prevent pre-cancerous lesions in women 16-26 years of age 23. High-grade disease was measured by the
presence of pre-cancerous lesions that were graded CIN 2 or 3 10, 23. These types of lesions were
thought to be the immediate precursors of cervical cancer when the trials were performed in
2000-2004 23. However, new guidelines regarding the natural history of cervical cancer were
introduced in Australia in 2005 which indicated scientists no longer believed this to be the case 7.
Previously, the guidelines for the treatment of cervical cancer implied a progression from CIN 1, CIN 2
and CIN 3 to cancer 7. The new belief is that “rather than an inevitable linear progression towards
cancer, most precursor HPV infections (CIN 2 and 3) acquired by women resolve without medical
intervention” 7.
If CIN 3 does change into invasive cancer the time frame for this to happen averages between 8.1 to
12.6 years 10. Yet the longest follow up study of the HPV vaccine during the clinical trials was only 4
years 10, 23. In addition, “the vast majority of women (16-26 years of age) clear or suppress HPV to
levels not associated with CIN 2 or 3 (high-grade disease) and for most women this occurs promptly”
10. Raffle et al state that modeling data from the United Kingdom suggests that eighty percent of
high-grade intraepithelial abnormalities will regress without intervention (as cited in 7).
Therefore, the correct assumption is that pre-cancerous lesions in this age-group are not an indication
that cervical cancer will develop from a high –risk HPV infection. The clinical trials do not provide
conclusive evidence that a reduced number of pre-cancerous lesions in women 16-26 years of age (even
if not previously infected with HPV 16/18) will reduce the incidence of cervical cancer in older women:
the age groups with the highest incidence of cervical cancer. The only conclusive evidence obtained
from the clinical trials in this age group was that the drug prevents infection from two out of many
strains of high-risk HPV’s identified in cervical cancer cases. It was assumed that fewer pre-cancerous
lesions in the vaccinated group indicated a reduction in cervical cancer cases in older women, but the
evidence discussed above suggests otherwise.

Promotion of Benefits and Risks of the Vaccine
In 2006 when the HPV vaccine was licensed and marketed to females, the phase 3 clinical trials had
not been completed 25. In other words, the benefit and duration of this vaccine against cervical
cancer had not been established. The promotional campaigns for this vaccine were funded by the
vaccine manufacturer and promoted through professional medical associations in America 26. This
arrangement was established to ensure that the public received education about this vaccine from a
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trusted source 26. The pharmaceutical companies supplied the medical associations with ready-made
presentations and letters to promote Gardasil® as a preventative for cervical cancer: even though the
data was incomplete and it was primarily a guard against HPV viruses 25. Much of the promotional
material did not address the complexity of the issues surrounding the vaccine and did not provide
balanced advice regarding the risks and benefits of the vaccine 26.
By promoting the vaccine as a preventative for cancer, instead of a sexually transmitted infectious
disease, the HPV vaccine was placed in the non-communicable disease category thus enabling the
manufacturer to avoid public health officials who would have scrutinized a high-risk vaccination
campaign 26. In addition, a law was passed in the United States in 1986 that permits vaccine
manufacturers the right not to disclose known risks of vaccines to parents and guardians 27. It states
“manufacturers bear no liability for giving, or failing to give, accurate or complete information to
those vaccinated, and have only to provide relevant information to doctors, who must give patients
CDC Vaccine Information Statements. 49” (as cited in 27).
The effectiveness and duration of this vaccine against cervical cancer were unknown in 2006 yet
Gardasil® was named the pharmaceutical “brand of the year” for building a ‘market out of thin air’
26. In 2008 worldwide sales reached $1.4 billion 26. This was an HPV 16/18 vaccine being promoted as
a cervical cancer vaccine to females aged 9 -26; even though it had not been tested in females under
15 years of age 5.
Many adverse events to HPV vaccines were reported during the two and a half years following the
licensure of the vaccine 5. The US Centers for Disease Control (CDC) and the Food and Drug
Administration (FDA) operate the US Adverse Events Reporting System (VAERS) 5. This is a voluntary,
national, passive surveillance system set up to monitor the adverse events to vaccines; it enables
manufacturers, health professionals and patients to report adverse reactions 5.
Although an analysis of the postlicensure safety surveillance data for the HPV vaccine has been
performed, the analysis only included adverse event data from the US 5. This is despite Gardasil®
being licensed in many foreign countries 5. The decision to use only American data was justified on
the grounds that US data offers more complete information and is more feasible for follow up studies
for medical review 5. Slade et al state 70% of the adverse event reports in their analysis came from
the manufacturer 5. Of these reports, 90% did not provide sufficient identifying information to allow
medical review of the individual cases 5. As a result of this failure in the system, VAERS data cannot
be used to infer causal associations between vaccines and adverse events 5. This also nullifies the
stated reason for excluding adverse event data from foreign countries, as the majority of the data did
not permit medical review. This shows an absence of rigorous surveillance and analysis of adverse
events which is essential in determining the safety of the vaccine.
The adverse events reported to VAERS included hypersensitivity, anaphylaxis, Guillaine-Barre
syndrome, transverse myelitis, pancreatitis, venous thromboembolic events, seizures, deaths and
pregnancy abnormalities 5. An accurate comparison of adverse events, including congenital
abnormalities and spontaneous abortion after vaccination, cannot be made from the clinical trials
because an inert placebo was not used 25. The manufacturer funded clinical trials used the adjuvant,
aluminum, as the placebo in the unvaccinated group 25: a chemical known to be linked with serious
adverse events 28. Therefore, the safety data provided by the clinical trials is inadequate.
In addition, adverse events were only monitored for 15 days after the administration of the vaccine
25. An accurate picture of the harmful events of a vaccine must be obtained from a systematic,
prospective, long-term assessment of adverse events 5. Since 2006 there have been 94 deaths and
21,634 adverse events reported to VAERS 29. Of these events 4,386 have resulted in permanent
damage 29. The VAERS statistics are believed to represent only one-tenth of the population damaged
by the vaccine as this is a passive reporting system 5. There has been no systematic, active, longterm surveillance of the adverse events resulting from this vaccine since it was marketed five years
ago.
The evidence cited above illustrates there was no requirement for the manufacturer to prove this
vaccine was safe and effective before it was marketed to women.
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Discussion
There are many serious ethical and scientific concerns regarding the promotion of HPV vaccines to the
public. The lack of correlation between cervical cancer mortality and infection with high-risk HPV subtypes indicates that lifestyle and environmental factors play a significant role in the progression of HPV
infection to carcinoma. HPV vaccines have been promoted to women as a cervical cancer vaccine when
in fact they guard against only two of many HPV sub-types. They have also been promoted to women
before the efficacy and safety profile has been established.
Scientists used an inappropriate surrogate to determine the efficacy of HPV vaccines against cervical
cancer. The observation of pre-cancerous lesions in an age group that rarely gets cervical cancer, and in
which these lesions mostly clear without leading to cervical cancer, was not an adequate measure of
the possible reduction in cervical cancer incidence. This is particularly the case when many other HPV
sub-types can infect and cause cervical cancer. There were known risk factors for this disease yet the
clinical trials did not select the study group for these risk factors. Women have been misled by the
claim that the vaccine is 98% effective when this result was only obtained for the study group that was
not infected with HPV 16/18 prior to vaccination. The reality is that many women will already be
infected with HPV 16/18, as it is a common infection, and efficacy in this group was only 44%.
The health department admits that screening for high-risk HPV infection would identify a very large
number of women but only a few of these are at risk of cervical cancer 7. Taking a drug to prevent
infection from HPV 16 and 18 results in a similar situation – the majority of the women on the drug
would not be at risk of cervical cancer. Many of the pre-cancerous lesions identified in cervical cancer
screening and included in the incidence rates for cervical cancer, will remain sub-clinical throughout
life and would otherwise have gone unnoticed 16.
Vaccinating the majority of women for an infectious disease that is mostly asymptomatic can expose
the population to more harm than good. Screening programs are a safe and cost-effective measure of
reducing this disease and women still need to be screened after vaccination 7. It is time to question
the cost-benefit of exposing women to the potential harm of a vaccine when cervical cancer was
reduced to low levels in developed nations before a vaccine was introduced.

Conclusion
It can be claimed that HPV infection is a necessary precursor to most cervical cancers but if most HPV
infections do not progress to cervical cancer then a vaccine against two strains of many high-risk HPV
subtypes will not be beneficial to the majority of women.
HPV vaccines have been promoted to women as a cervical cancer vaccine without any definitive
evidence they will prevent cervical cancer. In addition, no long-term systematic surveillance has been
implemented to establish the safety of the vaccine over the 5 years it has been used. It is clear that
government policy decisions and the marketing of vaccines have not been based on the best available
scientific evidence. This is detrimental to the health of the population and needs to be addressed in
order to maintain trust in the institutions that are supposed to protect public health.
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Appendix 1: The Limitations of the Bosch et al, 1995 Study.

Whilst Bosch et al, 1995, claim their international study of 1000 tumors confirms the role of HPV’s as
the central etiological factor in cervical cancer worldwide, their evidence does not explain why there
is a higher risk of cervical cancer in developing nations than developed nations. They claim that “HPV
prevalence was remarkably homogonous among the countries’ 2. The statement that HPV’s are the
central etiological factor in cervical cancer development relies upon detection methods being ‘truly
sensitive and specific’ and ignores the epidemiological evidence that indicates co-factors are necessary
to initiate cancer development.
The limitations of this study are listed below:

1. This study only included 10 of 18 regions for which cervical cancer incidence has been recorded
2. It did not include Asia and India which have very high rates of cervical cancer
3. In each country the size of the study is limited and the cases cannot be claimed to be
representative.

4. The results alter according to the method of detection used. For example, analysis of the 66

HPV- negative specimens using additional HPV detection methods (eg. other primers) alters the
number of negative tumors to fewer than 5%.

5. In the final analysis HPV-negative results were only accepted from specimens with adjacent,
confirmed tumor tissue. ‘This was to avoid false-negative results’. However, by doing this the
researchers were influencing the result.

6. The researchers state that their prevalence estimate of 93% maybe slightly inflated because

the only restrictions for HPV-positive specimens were diagnostic confirmation and PCR
sufficiency.

7. Whilst it is stated that all HPV detection was carried out by one expert laboratory and by one

histological reviewer, it would be important for the results to be confirmed by another
reviewer to ensure there is agreement. This is because there is subjectivity in the
interpretation of the result. The study does not state that the results were checked by an
independent researcher.

The primary researchers involved with these studies have links to industries that profit from
vaccines 2, 14, 3, 13.
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Appendix 2: The Strength of Evidence for HPV types in Cervical Carcinomas

Despite the significant evidence illustrating environmental and lifestyle factors are implicated in the
etiology of this cancer, Bosch et al, stated in 1995 that epidemiological studies have shown that the
association of genital human papillomavirus with cervical cancer is “strong, independent of other risk
factors and consistent in several countries” 2. This contradicts all the evidence of previous
epidemiological studies. Prior to 1995 most scientists were claiming a multifactorial etiology for
cervical cancer. At this time, Bosch et al, realized it was necessary to show that HPV is present in all
cases of cervical cancer in order to prove that HPV is the main factor in cancer etiology. So they set out
to conduct an international study of HPV sub-types in invasive cervical cancer 2. The aim of this study
was to characterize the distribution of HPV types in cervical cancer in different geographical regions.
They state “this is essential to the development of vaccination strategies to curb the burden of cervical
cancer” 2. So even though HPV was not always found in carcinomas and the geographical distribution of
HPV sub-types had not been mapped Bosch et al, were carrying out this research with the aim of
developing a vaccine.
Prior to this study it was believed that HPV DNA rates in tumor specimens were about 60-90% 13. By
1995 it was believed that the filter in situ hybridization technique used to identify HPV DNA in
epidemiological studies in the eighties had inadequate specificity and sensitivity 13. There was of
great concern regarding the variation in laboratory methods with different levels of specificity and
sensitivity for detecting HPV DNA 13. Therefore a new biological technique was used in the Bosch et al
study that was believed to be highly specific and sensitive. This was polymerase chain reaction (PCR)
protocol based on consensus primers flanking a relative conserved region in the L1 gene of HPV 13. This
technique is also called MY09/11 13. They concluded from their study that new molecular biology
techniques are ‘truly sensitive and specific’ and they believed their result confirmed the plausibility of
HPV infection as the pre-cursor event leading to cervical cancer 2.
This claim has been made based upon a biological test and the IARC states case series can only provide
suggestive results and can never serve as a basis for causal inferences 6. A claim of causality based on
PCR tests ignores the influence of host characteristics and environmental factors that are known to
influence pathogenesis. Bosch et al, (1995) state “more than 35 distinct HPV types are known to infect
the genital tract complicating the detection and distinction of these agents” 2. This must be taken into
account when assessing the reliability and specificity of the tests.
The Bosch et al, (1995) study tested nearly 1000 tumors and the negative-HPV tumors were re-tested
using different methods 2. It was found that HPV DNA could be detected in “separate portions from the
same specimen, which raised the prevalence to 93% and even higher – “to 95% on re-analysis with PCR
using primers” 2, p.780. Franco believes that the article by Bosch et al, 1995, can be viewed as a
critical contribution to our understanding of the etiology of cervical cancer. He says ‘traces of HPV
were detected in 95% of all cervical cancers’ 13. On this basis he claims that ‘HPV infection might turn
out to be the first cause of a human cancer shown to be a necessary one’- even though this evidence is
dependent upon the detection method used and still leaves 5% of tumors without evidence of HPV
infection 13.
The sub-types of HPV have been found in the following frequencies globally - HPV 16 (50%) of cases,
HPV 18 (12%), HPV 45 (8%) and HPV 31(5%) 2. Prevalence of these types also varied geographically.
On the evidence of the Bosch et al study, Franco questions the existence of cervical cancers that are
induced by carcinogenic routes other than HPV infection 13. He suggests HPV free cancers might be
reflecting loss of the HPV genome as the disease progresses. This is speculation. Rather than accepting
that it’s possible some tumors are induced by factors other than HPV, he suggests researchers will have
to demonstrate that “failure to detect HPV DNA is not due to insufficient sensitivity” of the test 13.
Franco has taken the position that an absence of HPV genome is not because there is an absence of
HPV genome but rather a loss due to disease progression and he is assuming the HPV was there in the
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first place. This is interpreting the results to produce the desired outcome. It is not evidence-based
science.
In addition, if HPV DNA is found in organs and tissues where it is not expected to be found he claims
“researchers will have to prove that “an occassional HPV-tissue association is not due to insufficient
specificity or contamination” 13. Again Franco is providing an explanation for the unexpected result to
fit in with the desired outcome.
Franco states earlier in his article that “an easily diagnosed viral infection as the pre-cursor event
leading to cervical cancer calls for action on 2 fronts:

1. primary prevention by immunisation against HPV and
2. secondary prevention by cytology screening with testing for cervical HPV infection.
It would appear that the researchers were pre-empting the result in order to find evidence to support
the preventative measures they would like to implement: vaccination programs.
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